ValiRx PLC Update on Recent Presentations
October 13 2016 - 1:00AM
RNS Non-Regulatory
TIDMVAL
ValiRx PLC
13 October 2016
VALIRX PLC
("ValiRx", "the Company" or "the Group")
UPDATE ON RECENT PRESENTATIONS
London, UK., 13 October 2016: ValiRx Plc (AIM: VAL), a life
science company, which focuses on clinical stage cancer therapeutic
development, taking proprietary & novel technology for
precision medicines towards commercialisation and partnering, is
pleased to provide an update on recent presentations.
A presentation, in the form of a poster, was given by the
Company and its Principle Clinical Investigator at the prestigious
European Society for Medical Oncology ("ESMO") Conference on
Monday, 10 October 2016 in Copenhagen.
The presentation provided data from the Company's
"First-in-human (FIH) phase I/II, dose escalation and
pharmacokinetic (PK) study to show the safety and tolerability of
VAL201 in patients with advanced prostate cancer and other advanced
solid tumours."
The poster showed early indications of efficacy in advanced
prostate cancer with no drug-related serious adverse events
recorded, as was previously announced via RNS on 13 September 2016.
The study continues with expansion into other tumour types. An
Endometriosis trial is also being planned.
A link to the poster will shortly be made available on the
'News' section of the ValiRx website: www.valirx.com.
The Company also recently gave presentations to investors at the
Shares Investor Evening in Edinburgh on Wednesday, 5 October 2016
and at the Proactive Investor One2One Forum in Mayfair, London on
Thursday, 6 October 2016.
A video link to Dr George Morris, COO's presentation in
Edinburgh is also available on the 'News/Video' section of the
ValiRx's website.
All of these events were well attended.
ValiRx intends to continue presenting clinical data at various
international conferences in the future and it will update the
market on progress regularly.
Dr Satu Vainikka, CEO, commented:
"We are delighted with the enthusiastic reception from the
international biopharma community over our progress in oncology
therapeutic development in this exciting new personalized field of
medicine".
"We are extremely pleased with the results of our clinical
trials and of the preliminary results on endometriosis. We look
forward to updating the market on developments in due course".
*** ENDS ***
For more information, please contact:
ValiRx Plc Tel: +44 (0) 20
3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20
3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879
458 364
tarquin.edwards@valirx.com
Mark Treharne, Corporate Development Tel: +44 (0) 7736
Manager 564 686
mark.treharne@valirx.com
Notes for Editors
ValiRx Plc
ValiRx is a biotechnology oncology focussed company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's three classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from Word class institutions, such
as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the Alternative Investment Market ("AIM")
of the London Stock Exchange in October 2006 and trades under the
ticker symbol: VAL.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAMTBBTMBIBTLF
(END) Dow Jones Newswires
October 13, 2016 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024